BLPH - Bellerophon launches late-stage study of INOpulse in lung-scarring diseases

The first patient has been enrolled in a Phase 3 clinical trial, REBUILD, evaluating Bellerophon Therapeutics' (BLPH) INOpulse, a pulsed inhaled nitric oxide therapy, for the potential treatment of fibrotic interstitial lung disease, an umbrella term for a large group of disorders that cause scarring (fibrosis) of the lungs.The primary endpoint is the change from baseline to month 4 in moderate-to-vigorous physical activity as measured by actigraphy (the patient wears a sensor that measures gross motor activity).The estimated primary completion date is June 2022.Shares up 1% premarket on light volume.

For further details see:

Bellerophon launches late-stage study of INOpulse in lung-scarring diseases